EMCURE

Emcure Pharmaceuticals Limited

Source: NSE · Updated 4 Nov, 11:32 pm IST

Filed 3 Nov, 01:44 pm IST Q2 FY27 (Sep ’26)Consolidated₹ millions

Revenue

28,204.71

▲ 24.3% vs Q2 FY26

Operating profit (EBITDA, derived from filing)

5,878.37

▲ 23.6% vs Q2 FY26

Net profit

3,250.68

▲ 29.3% vs Q2 FY26

EPS (₹)

17.16

▲ 33.5% vs Q2 FY26

Operating margin

20.8%

−10 bps vs Q2 FY26

Net margin

11.5%

+40 bps vs Q2 FY26

Revenue up, profit up vs Q2 FY26

Revenue+24% vs Q2 FY26 · +9% vs Q1 FY27

Profit+29% vs Q2 FY26 · +11% vs Q1 FY27

View official filing ↗

Numbers from the company's structured XBRL filing on NSE, cross-checked with P&L totals.

Previous-quarter and year-ago figures: as originally reported in those quarters' NSE filings; filing PDF not available to confirm restatements.

Quarter comparison

Item	Q2 FY27 (Sep ’26)	Q1 FY27 (Jun ’26)	vs Q1 FY27	Q2 FY26 (Sep ’25)	vs Q2 FY26
Revenue from operations	28,204.71	25,804.47	▲ 9.3%	22,698.22	▲ 24.3%
Other income	32.54	20.71	▲ 57.1%	31.23	▲ 4.2%
Total income	28,237.25	25,825.18	▲ 9.3%	22,729.45	▲ 24.2%
Total expenses	23,778.73	21,889.92	▲ 8.6%	19,315.28	▲ 23.1%
Operating profit (EBITDA)*	5,878.37	5,324.96	▲ 10.4%	4,754.79	▲ 23.6%
Profit before tax	4,458.52	3,935.26	▲ 13.3%	3,414.17	▲ 30.6%
Tax expense	1,207.84	1,010.33	▲ 19.5%	900.47	▲ 34.1%
Net profit	3,250.68	2,924.93	▲ 11.1%	2,513.7	▲ 29.3%
EPS (₹)	17.16	15.50	▲ 10.7%	12.85	▲ 33.5%
Operating margin	20.8%	20.6%	+20 bps	20.9%	−10 bps
Net margin	11.5%	11.3%	+20 bps	11.1%	+40 bps

Showing Q2 FY27 (Sep ’26) and change vs Q2 FY26. Turn your phone sideways for Q1 FY27 (Jun ’26).

Figures in ₹ millions except EPS. Consolidated figures from the company's XBRL filing on NSE. Each row is shown only if it reconciles with the others (e.g. PBT − tax = net profit); rows we couldn't verify are left out. Net margin = net profit ÷ revenue. *Operating profit (EBITDA), derived from the filing: profit before exceptional items and tax + finance costs + depreciation − other income. Operating margin = EBITDA ÷ revenue.

All Emcure Pharmaceuticals results, dividends & filings ›

Other results filed 3 Nov

HEGAM HEG Advanced Materials Limited›PARAGMILK Parag Milk Foods Limited›AARNAV Aarnav Fashions Limited›DNAMEDIA Diligent Media Corporation Limited›FRACTAL Fractal Analytics Limited›ALLCARGO Allcargo Logistics Limited›IONEXCHANG ION Exchange (India) Limited›MPSLTD MPS Limited›CLEANMAX Clean Max Enviro Energy Solutions Limited›ONIDA Onida Electronics Limited›RSYSTEMS R Systems International Limited›INDIANCARD Indian Card Clothing Company Limited›

Today's results ›

EMCURE PHARMACEUTICALS Q2 FY27 ; NET PROFIT UP 29% AT ₹325 CR (YOY), UP 11% (QOQ)

REVENUE UP 24% AT ₹2,820 CR (YOY), UP 9% (QOQ)

EBITDA UP 24% AT ₹588 CR (YOY), UP 10% (QOQ)

MARGINS AT 20.8% VS 20.9% (YOY), 20.6% (QOQ)

https://resultkal.com/r/emcure-2026-11-03
Source: NSE filing · not investment advice

FAQ

When did Emcure Pharmaceuticals announce Q2 FY27 results?

Emcure Pharmaceuticals filed its results on NSE on 3 Nov, 01:44 pm IST.

What does QoQ and YoY mean?

QoQ compares with the previous quarter; YoY compares with the same quarter last year. Growth is calculated from the figures in the filing.

Are these Emcure Pharmaceuticals figures official?

They are auto-read from the company's NSE filing and may contain errors. Always confirm with the official PDF linked on this page.

Explore

Today's results Results this week Q2 FY27 results dates Dividend stocks this week Bonus issue 2026 Stock split 2026

Figures are auto-read from the company's NSE filing and may contain errors. Check the official filing before deciding. Not investment advice.

← EMCURE overview